ArticleHealth science reports2025
Pretreatment HIV-1 Drug Resistance Among Newly Diagnosed People in Eastern Ethiopia.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: In Ethiopia, HIV-1 pretreatment drug resistance (PDR) data are limited owing to a lack of routine genotyping resistance tests. This study aimed to determine the prevalence of HIV-1 PDR mutations and genetic diversity among newly diagnosed people with HIV in eastern Ethiopia. Methods: HIV RNA was extracted using Abbott m2000sp. HIV-1 partial pol genes were amplified and sequenced using the Sanger dideoxy method. DRM profiles were examined and interpreted according to the calibrated population resistance (CPR) and Stanford University HIV drug resistance algorithms. A maximum likelihood phylogenetic tree was constructed using PhyML version 3.0 and visualized using the iTOL tool. Bivariable and multivariable logistic regression models were used to identify baseline factors associated with outcomes at a Results: Among newly diagnosed individuals with baseline viral load (≥ 1000 copies/mL) and amplifications were successful, the genotyping success rate was 78.4%. Among the isolates successfully sequenced, three HIV-1 strains were detected, of which 97.1% had HIV-1 subtype C, 1.4% A1C, and 1.4% CF1 recombinant. According to the Stanford HIVDR algorithm, 21.7% of people had at least one drug associated PDR mutation, whereas CPR reported 14.5% DRMs. NNRTIs had the highest PDR mutation rate (13.0%), followed by NRTIs (7.2%) and PIs (2.9%). The most commonly observed major DRMs were: NNRTIs (K103N and G190A), NRTIs (D67G and L210W), and PIs (L90M and I54S). Patients who were bedridden at enrollment were more likely to harbor PDR mutations (AOR: 5.4; 95% CI: 1.53-30.7). Conclusions: High PDR levels, predominantly for NNRTIs, are observed. During clinical follow-up, special attention should be given to bedridden functional status patients. Further surveillance studies are needed to evaluate the long-term effects of prolonged accumulation of resistance and its transmission on current ART regimens and to design appropriate interventions to halt the HIV epidemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.